ClinicalTrials.gg
RecruitingNCT07516093Updated Aug 31, 2026

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

A Phase 3 interventional study of NX-5948 and Pirtobrutinib in B-cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Nurix Therapeutics, Inc.. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Nurix Therapeutics, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
620
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing pirtobrutinib in Lymphoma, B-Cell — 3 open to participants now, 8 under way, 6 of them phase 3. pirtobrutinib · Lymphoma, B-Cell.

Planned enrollment
3rd of 10
620 · median 391
Started
2026
with 1 other
Phase 3
6 of 10
2 open now
Registered
9th of 10
by date
Lead sponsor
1 of 10
Nurix Therapeutics, Inc.

Among the 10 studies testing pirtobrutinib in Lymphoma, B-Cell, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2026, is one of 6 in phase 3, and was the 9th registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

3 of the 10 studies testing pirtobrutinib in Lymphoma, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About pirtobrutinib

pirtobrutinib: first FDA approval 2023 (JAYPIRCA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing pirtobrutinib in Lymphoma, B-Cell, or all of them as a file.
02

Study summary

The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent Bruton tyrosine kinase inhibitor (cBTKi) treatment.

03

Conditions studied

  • B-cell Lymphoma
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Keywords

  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Degrader
  • B-cell malignancy
  • BTKi
  • Bexobrutideg
  • Pirtobrutinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • (ECOG) performance status of 0 to 2
  • Adequate organ and bone marrow function
  • Confirmed diagnosis of CLL/SLL that meets iwCLL 2018 criteria for diagnosis and systemic treatment
  • Received at least 1 for CLL/SLL that included a cBTKi and must have documented disease progression during treatment with, or after discontinuation of, the cBTKi
  • Participants with SLL must have by computed tomography (CT) per iwCLL

Key Exclusion Criteria:

  • Known or suspected prolymphocytic leukemia or Richter's transformation at any time preceding enrollment
  • agent or anticancer therapy within 5 half-lives or 14 days (whichever is shorter) prior to planned start of study treatment
  • Ongoing systemic ≥10 mg/day prednisone or equivalent
  • Previously treated with a BTK degrader or a noncovalent BTKi
  • Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, placement of a coronary arterial stent, or any other significant cardiac condition within 6 months of planned start of study treatment
  • Thromboembolic events, stroke, or intracranial hemorrhage within 6 months of planned start of study treatment

Note: Other Inclusion/Exclusion criteria may apply as defined in the protocol.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
620 participants (estimated)

Study arms

  • Experimental
    Arm A: NX-5948

    Drug: NX-5948

  • Experimental
    Arm B: Pirtobrutinib

    Drug: Pirtobrutinib

Interventions

  • Administered orally once daily

    Also known as: Bexobrutideg

  • Administered orally once daily per prescribing information

    Also known as: JAYPIRCA

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) as assessed by Independent Review Committee (IRC)

    Time from randomization to disease progression per 2018 International Workshop on CLL (iwCLL) or death due to any cause, whichever is earlier

    Time frame: Up to approximately 3.5 years

  2. Objective response rate (ORR) without partial response with lymphocytosis (PR-L) as assessed by IRC

    Percentage of participants with best overall response of complete response (CR)/CR with incomplete marrow recovery (CRi), partial response (PR), or nodular PR, as assessed per 2018 iwCLL guidelines

    Time frame: Up to approximately 2.5 years

Secondary outcomes

  1. Overall survival

    Time from randomization to death from any cause

    Time frame: Up to approximately 7 years

  2. PFS as assessed by the investigator

    Time from randomization to disease progression or death due to any cause, whichever is earlier

    Time frame: Up to approximately 3.5 years

  3. Objective response rate (ORR) with and without partial response with lymphocytosis (PR-L) as assessed by IRC and investigator

    Percentage of participants with best overall response of complete response (CR)/CR with incomplete marrow recovery (CRi), partial response (PR) or nodular PR, or PR-L (for ORR with PR-L), as assessed per 2018 International Workshop on CLL (iwCLL) guidelines

    Time frame: Up to approximately 3.5 years

  4. Duration of response with and without PR-L as assessed by IRC and investigator

    Time from the date of the first response to documented disease progression or death due to any cause, whichever is earlier

    Time frame: Up to approximately 3.5 years

  5. Time to next anti-CLL/SLL treatment as assessed by IRC and by investigator

    Time from randomization to the date of next anti-CLL/SLL treatment

    Time frame: Up to approximately 3.5 years

  6. Change from baseline in global health status/quality of life on the European Organization for Research and Treatment of Cancer Quality of Life Cancer Questionnaire C30 with CLL module (EORTC QLQ-C30-CLL17)

    Percentage of participants with a clinically meaningful change from baseline using the EORTC QLQ-C30-CLL17 questionnaire to assess global health and overall quality of life

    Time frame: Baseline and up to approximately 3.5 years

  7. Change from baseline in EuroQol-5 Dimensions, 5-level Questionnaire (EQ-5D-5L)

    Percentage of participants with a clinically meaningful change from baseline using the EQ-5D-5L questionnaire to assess health outcomes

    Time frame: Baseline and up to approximately 3.5 years

  8. Number of participants with treatment-emergent adverse events

    Time frame: Up to approximately 3.5 years

  9. Pharmacokinetic profile of NX-5948

    NX-5948 concentrations in blood samples

    Time frame: Up to Cycle 13 Day 1 (each cycle is 28 days)

  10. Number of participants with clinically significant changes from baseline in laboratory parameters

    Laboratory parameters may include hematology, clinical chemistry, and urinalysis

    Time frame: Up to approximately 3.5 years

  11. Number of participants with clinically significant changes from baseline in vital signs

    Vital signs include blood pressure, heart and respiratory rates, pulse oximetry, and temperature

    Time frame: Up to approximately 3.5 years

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Oct 2029, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 7, 2026
StartActual
Aug 3, 2026
Primary completionEst.
Oct 2029
CompletionEst.
Aug 2033
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07516093
Lead sponsor
Nurix Therapeutics, Inc.
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
Aug 3, 2026
Primary completion
Oct 2029 (estimated)
Completion
Aug 2033 (estimated)
Last update
Aug 31, 2026

Study contacts

Additional Site Contact Information
Contact
clinicaltrials@nurixtx.com
415-417-3418
Study Director
study director · Nurix Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: NX-5948 · Pirtobrutinib

Start the discussion